![]() |
|
Selected examples of halogenated
corticosteroids.
|
Most of us are familiar with drug
products such as Flonase®, Flovent and Advair, which are used for the
management of asthma and chronic obstructive pulmonary disease (COPD). In 2013,
Advair racked up over $4.8 billion dollars in sales. Flonase and Advair contain
a 6,9-a-difluorinated corticosteroid
derivative called fluticasone propionate (see scheme below, structure 8), which
is responsible for inducing the potent anti-inflammatory effects of the drugs. The
9a-halogenated glucocorticosteroid
series was first discovered in 1953 by Fried and Sabo (J. Am. Chem. Soc. 1953, 75, 2273), who noted that
anti-inflammatory bioactivity was inversely correlated with the size of the
halogen atom substituted at C9. The activity trend in the C9 series was: I <
Br < Cl < F, with the 9a-fluoro
derivatives (representative examples shown above) exhibiting a >10-fold
increase in binding affinity to glucocorticoid receptors compared to the parent
hormones. The 9a-fluoro substituent
also impedes oxidation of the proximal 11-hydroxy group, providing increased
duration of action. Incorporation of a 6a-fluoro
prevents hydroxylation at this position. Interestingly, the rarely encountered
fluorinated 20-thioester moiety of fluticasone propionate was incorporated to
exploit a hepatic inactivation mechanism that affords its corresponding
carboxylic acid. The lack of bioactivity associated with this carboxylic acid metabolite
results in vastly reduced undesired systemic exposure of the parent drug.
It is now well known that the fluorine atom’s electronegativity, size, omniphobicity/lipophilicity and electrostatic interactions can dramatically influence the binding affinity of a fluorinated ligand for its biological protein target (for an excellent medicinal chemistry resource, see this). Indeed, a single substitution of a fluorine atom in exchange for hydrogen can completely change the biological properties of a small molecule. In fact, the so-called ‘fluorine scan’ is currently a routine approach used in the development of a drug candidate.
It is now well known that the fluorine atom’s electronegativity, size, omniphobicity/lipophilicity and electrostatic interactions can dramatically influence the binding affinity of a fluorinated ligand for its biological protein target (for an excellent medicinal chemistry resource, see this). Indeed, a single substitution of a fluorine atom in exchange for hydrogen can completely change the biological properties of a small molecule. In fact, the so-called ‘fluorine scan’ is currently a routine approach used in the development of a drug candidate.
As described in a recent patent by
Hovione Ltd., fluticasone propionate is manufactured by means of a rather lengthy
semisynthetic derivatization process, wherein fluorine atoms are sequentially
introduced by functional group interconversion reactions. For example, the 6a-fluoro substituent is installed by
electrophilic fluorination of a dienol benzoate intermediate (2 à 3), itself derived
from prednisone acetate. The embedded 9a-fluoro
is then incorporated by subsequent ring-opening of a 9,11-oxirane ring with
aqueous hydrofluoric acid. Finally, a 2014 Organic
Process Research and Development report disclosed an effective method for
introduction of the fluorinated 20-thioester moiety involving decarboxylative
fluorination of a carboxylic acid intermediate (7 à 8) using silver nitrate and
Selectfluor. The reaction to produce fluticasone propionate was demonstrated on
95-gram scale.
The overall API manufacturing
process for fluticasone propionate production is generally quite efficient, but
somewhat linear in nature. A more concise synthetic entry into the halogenated
corticosteroid structural framework is therefore highly sought after.
Unfortunately, Nature does not produce fluorinated steroids and so enzymatic
biotransformation, in this case, does not represent a viable solution. Synthetic
methods for direct fluorination of
the steroid nucleus, with ‘enzyme-like’ precision over regio- and
stereoselectivity, would provide great utility for the efficient production of
clinically relevant halogenated glucocorticoids such as fluticasone. A brief
survey of recently reported fluorination protocols that do not require
extensive pre-functionalization of steroidal substrates (i.e. ‘direct’ fluorination
methods) is provided below.
In 2012, the laboratory of John T.
Groves at Princeton University reported a cytochrome P450-inspired method for
oxidative C-H fluorination of cycloalkanes that is catalyzed by a unique
manganese porphyrin complex, in combination with stoichiometric additives. The
authors applied their technology to the steroid 5a-androstan-17-one,
which contains no less than 28 unactivated sp3
C-H bonds. Presumably due to electronic deactivation of the D ring, in conjunction
with steric hindrance of rings B and C, only the C2 and C3 positions on the A
ring were fluorinated with good conversion and high stereoselectivity. The
diastereoselectivity is likely the result of steric shielding of the b-face by the axial C19 methyl substituent.
Mechanistic analysis of the transformation suggested that C-H bond cleavage of
the cycloalkane is mediated by an oxomanganese(V) catalytic intermediate [oxo-Mn(V),
structure shown above], produced by oxidation of the pre-catalyst, manganese(III)TMP-chloride
[Mn(TMP)Cl]. The oxo-Mn(V) species abstracts a hydrogen atom from the substrate
to produce a transient carbon-centered radical. The radical is then trapped by
F delivery from an unusual trans-difluoromanganese(IV)TMP
complex, culminating in hydrocarbon fluorination with extrusion of a manganese(III)
intermediate back into the catalytic cycle. The putative fluorinating agent,
Mn(IV)(TMP)F2, was isolated and structurally characterized by X-ray
crystallography. As described in a 2013 Nature
Protocols manuscript, Groves’ C-H fluorination procedure requires only a
typical laboratory fume hood and ordinary glassware.
The direct regio- and
stereocontrolled a-fluorination of allo-pregnanedione (shown above) was
demonstrated in 2011 by MacMillan’s group. A primary amine-functionalized
Cinchona alkaloid organocatalyst selectively activates the ketone carbonyl of
the substrate’s A-ring, giving rise to a conformationally restricted enamine, which
succumbs to electrophilic fluorination in a stereocontrolled fashion. Catalyst
controlled regio- and stereoselectivity are particularly impressive in this
instance given that allo-pregnanedione
contains two ketones and three a-methylene
sites. The same methodology was also applied to the steroid cholestanone and,
again, fluorination was achieved with complete regiocontrol and outstanding
efficiency.
Ritter’s group at Harvard has
developed an operationally simple ipso
deoxyfluorination reaction that provides expedient access to 3-fluoro-estrone
in a single operation, without the need for pre-functionalization. The reaction
proceeds via the intermediacy of a 2-aryloxyimidazolium bifluoride salt
(bracketed intermediate above), formed by condensation of the estrone A-ring phenol
with Ritter’s stoichiometric fluorinating reagent. Proximity-induced
nucleophilic fluorination by hydrogen bonded fluoride then produces the steroidal
fluoro-arene product. Late-stage steroid fluorination techniques such as this
one could potentially provide access to 18F-radiolabelled
fluorosteroids which have shown promise as radiotracer imaging agents for
cancer.
While none of the protocols
described above will immediately revolutionize the manner in which halogenated
corticosteroids are manufactured, this general line of research, which has been
initiated with some very exiting preliminary results, may one day lead to more
step-economical syntheses of important APIs such as fluticasone propionate.





